Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
5-Fluorouracil (5-FU) resistance pathways represent the multifaceted biological mechanisms that cancer cells utilize to evade the cytotoxic effects of 5-FU, a widely used antimetabolite (Longley et al., 2003 [1]). The primary mechanism involves the upregulation of thymidylate synthase (TYMS), the enzyme 5-FU is designed to inhibit, thereby maintaining dTMP production for DNA synthesis (Peters et al., 2002 [2]). Additionally, high levels of dihydropyrimidine dehydrogenase (DPYD) can lead to rapid catabolism of the drug, reducing its bioavailability and therapeutic impact (Diasio and Johnson, 1999 [3]). Resistance is also linked to deficiencies in activating enzymes such as orotate phosphoribosyltransferase (OPRT) and thymidine phosphorylase (TYMP), which are necessary to convert 5-FU into its active metabolites (Ichikawa et al., 2003 [4]). Furthermore, alterations in apoptotic signaling, such as p53 mutations or overexpression of anti-apoptotic proteins like Bcl-2, allow cells to survive 5-FU-induced DNA damage (Zhang et al., 2008 [5]). Changes in drug transport, specifically the overexpression of multidrug resistance-associated proteins (MRPs), can further decrease intracellular drug concentration (Longley et al., 2003 [1]). Understanding these pathways is vital for developing combination therapies and personalized treatment strategies to overcome chemoresistance in various malignancies, particularly colorectal cancer. References: [1] Longley DB, et al. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330-8. [2] Peters GJ, et al. Thymidylate synthase and drug resistance. Eur J Cancer. 2002;38(6):758-66. [3] Diasio RB, Johnson MR. Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res. 1999;5(10):2672-3. [4] Ichikawa W, et al. Both gene expression of thymidylate synthase and orotate phosphoribosyltransferase predict response to 5-fluorouracil. Clin Cancer Res. 2003;9(11):4059-64. [5] Zhang N, et al. 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules. 2008;13(8):1551-69.
Inhibition of thymidylate synthase and incorporation of fluoronucleotides into RNA and DNA, leading to cell cycle arrest and apoptosis; resistance mechanisms counteract these effects through enzyme upregulation or altered metabolism (Longley et al., 2003 [1]).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 5-Fluorouracil (5-FU) resistance pathways (5-FU resistance).